Revvity Nitrendipine, -, 25µci (925kbq)

Revvity Nitrendipine acts as an antagonist at dihydropyridine calcium channel blockers (CCB), and is used to treat primary hypertension. - REVPFZ (Additional S&H Or Hazmat Fees May Apply)

Revvity We offer both agonist and antagonist radioligands for autoradiographic visualization or performing saturation and competition assays to determine receptor expression levels (B_max), dissociation constants (K_d), association and dissociation rates (k_on and k_off), and inhibitor constants (K_i) for a variety of receptors. We develop our radioligands to the highest specific activity possible and provide high purity resulting in low non-specific binding products. Each of our ultra-pure radioligands is fully characterized for pharmacological action and validated in receptor binding assays. - REVPFZ (Additional S&H Or Hazmat Fees May Apply)

Revvity Radiolabeled ligands remain the most sensitive method for probing receptor binding biology; yielding unprecedented sensitivity gives results that technicians and scientists can trust. For over 50 years, Revvity has been a leading supplier of New England Nuclear (NEN) radiochemicals, liquid scintillation cocktails, vials and nuclear counting detection instruments. - REVPFZ (Additional S&H Or Hazmat Fees May Apply)

Revvity References for NET741: - REVPFZ (Additional S&H Or Hazmat Fees May Apply)

Schoemaker, H., (1992) Polyamines allosterically modulate [3H]nitrendipine binding to the voltage-sensitive calcium channel in rat brain, In European Journal of Pharmacology: Molecular Pharmacology, 225 (2): 167-169.Janis, R. A., Krol, g. J., Noe, A. J. and Pan, M. (1983), Radioreceptor and High-Performance Liquid Chromatographic Assays for the Calcium Channel Antagonist Nitrendipine in Serum. The Journal of Clinical Pharmacology, 23: 266–273.